Biomed Life Science Day 2026

Ana Maria is an international TV, radio and print journalist with 20 years at CNN. She hosted 'Escenario' from LA, reaching 40M+ viewers across 45 countries. In 2017, she pivoted to finance as top anchor for CNN Money Switzerland until 2020. She is now an independent journalist, TV host, event moderator and media trainer across Switzerland and Europe.

Dominik is Co-Founder & CEO of Tubulis. From early founding, he secured prestigious startup awards, including MIT Innovator Under 35 (2019). He is also a life science investor in young European biotech companies. Prior to Tubulis, Dominik worked at Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and as group leader at LMU Munich. He holds a PhD from Humboldt University Berlin and studied Chemistry/Economics at Heinrich Heine University Düsseldorf.

Christian is Chair of the Board of Tubulis and a serial biotech entrepreneur who co-founded several life science companies (SNIPR Biome, Freeline, Gyroscope, Quadrucept, Folium). Since 2015, Christian co-founded and serves as CEO of SNIPR Biome. Previously he served as CEO of Kymab, CSO/Head R&D of Zealand Pharma, and held R&D/corporate roles at Novo Nordisk. He holds a Veterinary Medicine, PhD, and MD degree from Uni. of Copenhagen, and an MBA from Uni. of Lausanne.

Valentin is a life sciences VC investor with 15+ years as private investor/board member in startups from seed to IPO. Prior to joining Biomed in 2015, he founded VP Venture Partners AG (2020) for early-stage non-therapeutic ventures, and was Principal at Nextech Invest (an oncology-focused VC firm). He holds a PhD in Neuroscience (Rockefeller), MSc Cognitive/Neural Systems (BU), and MSc Mechanical Engineering (ETH Zurich).

Michael is an experienced life science entrepreneur who joined Biomed in 2019. He has successfully built multiple startups, including GlycoVaxyn (acquired by GSK for $212M in 2015), and was Chairman of the Board of Inositec (acquired by Vifor Pharma) and CBO and Board Member of Polyneuron Pharmaceuticals. He also coaches Swiss startups as an Innosuisse coach. Michael holds a PhD in microbiology from ETHZ and is an inventor/author with publications in Science and PNAS.

Ulf is a serial biotech entrepreneur with over 20 years experience in capital markets and business development. He has founded and scaled multiple companies to successful exits, including NBE-Therapeutics (acquired by Boehringer Ingelheim in 2021) and 4-Antibody (acquired by Agenus in 2012). He is currently Co-Founder & CEO of T-CURX, a BiomedInvest IV portfolio company. He has raised over CHF 100M in venture funding and negotiated commercial deals exceeding EUR 1Bn in value.

Ruben Herrendorff is CEO of NXI Therapeutics, a BiomedInvest IV portfolio company. He is a seasoned biotech executive with deep expertise in drug development and company building. Previously, he co-founded and was CEO of Polyneuron Pharmaceuticals. Ruben holds a PhD in Pharmaceutical Sciences from University of Basel and has secured significant venture funding for innovative therapeutics.